Skip to main content

Table 7 Summary of non-controlled studies and outcomes

From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review

Effects of omalizumab in patients with urticaria: uncontrolled studies
Author (year) Urticary type N No response Partial response Complete response
Ivyanskiy (2012) CIU 12, AIU 6, DPU 1 19 3 5 11
Ferrer (2011) CSU 9 2 5 2
Groffik (2011) CSU 9 0 4 5
Sánchez-Machín (2011) CSU 1 0 0 1
Saavedra (2011) CSU 1 0 0 1
Krause (2010) Dermographic U 1 0 0 1
Buller Kotte (2010) Heat U 1 0 0 1
Binslej-Jensen(2010) DPU 1 0 0 1
Magerl (2010) CSU 8 0 1 7
Al-Ahmad (2010) AIU 3 0 0 3
Kemoli (2010) AIU 1 0 0 1
Sabroe (2010) Cholinergic U 1 1 0 0
Waiber (2009) Solar U 1 0 1 0
Maspero (2009) AIU 1 0 0 1
Kaplan (2008) AIU 12 1 4 7
Güzelbey (2008) Solar U 1 0 0 1
Metz (2008) Cholinergic U 1 0 0 1
Godse (2008) CSU 3 0 0 3
Sands (2007) CAU 3 0 0 3
Spector (2007) 2 AIU, 1 CSU 3 0 0 3
TOTAL   78 7(8,9%) 20 (25,6%) 51 (65,3%)
  1. CIU: Chronic Idiopathic Urticaria; AIU: Aspirin induced Urticaria; DPU: Delayed Pressure Urticaria; CSU: Chronic Spontaneous Urticaria; CAU: Chronic Autoinmune Urticaria.